First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 88, Issue 3, 2010, Pages 159-170

  Wurst, Keele E ^a   Poole, Charles ^b   Ephross, Sara A ^a   Olshan, Andrew F ^b  

^a GLAXOSMITHKLINE   (United States)

^b IL   (United States)

Author keywords

Cardiac defects; Congenital defects; Meta analysis; Paroxetine

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONFIDENCE INTERVAL; CONGENITAL HEART MALFORMATION; EPIDEMIOLOGICAL DATA; FIRST TRIMESTER PREGNANCY; GENETIC HETEROGENEITY; HUMAN; MEDICAL INFORMATION; MEDICAL LITERATURE; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; ADULT; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; ODDS RATIO; PAROXETINE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; SEROTONIN UPTAKE INHIBITORS;

EID: 77949294245     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20627     Document Type: Article

References (45)

1. Alwan S, Reefhuis J, Rasmussen S, et al. 2005. Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects. Birth Defects Res A Clin Mol Teratol 73:291.
2. Alwan S, Reefhuis J, Rasmussen SA, et al. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684-2692.
3. Bakker MK, Kerstjens-Frederikse WS, Van den Berg MD, et al. 2006. Use of selective serotonin reuptake inhibitors in early pregnancy and risk of cardiac malformations. Pharmacoepidemiol Drug Safety 15:S81.
4. Bar-Oz B, Einarson T, Einarson A, et al. 2007. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 29:918-926.
5. Begg CB, Mazumdar M. 1994. Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101.
6. Berard A, Ramos E, Rey E, et al. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80:18-27.
7. Botto LD, Correa A, Erickson JD. 2001. Racial and temporal variations in the prevalence of heart defects. Pediatrics 107:32-39.
8. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. 2003. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142:402-8.
9. Chambers CD, Braddock S, Briggs G, et al. 2001. Postmarketing surveillance for human teratogenecity: a model approach. Teratology 64:252-261.
10. Chambers CD. 2007. Birth outcomes among pregnant women taking paroxetine (Paxil). Personal communication.
11. Cochran W. 1950. The comparison of percentages in matched samples. Biometrika 37:256-266.
12. Cole JA, Ng EW, Ephross SA, Cosmatos IS. 2006. Paroxetine in the first trimester of pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Safety 15:S6.
13. Cole JA, Ephross SA, Cosmatos IS, Walker AM. 2007. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Safety 16:1075-85.
14. Davis R, Rubanowice D, McPhillips H, et al. 2007. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Safety 16:1086-1094.
15. Diav-Citrin O, Shectman S, Weinbaum D, et al. 2005. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reprod Toxicol 20:459.
16. Diav-Citrin O, Shectman S, Weinbaum D, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 66:695-705.
17. Duval S, Tweedie R. 2000. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455-463.
18. Egger M, Davey SG, Schneider M, Minder C. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
19. Egger M, Dickersin K, Davey Smith G. 2001. Problems and limitations in conducting systematic reviews. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing. pp. 43-68.
20. Einarson A, Pistelli A, Desantis M, et al. 2008b. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 165:749-752.
21. Ericson A, Kallen B, Wiholm B. 1999. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 55:503-508.
22. Greenland S. 1998. Meta-analysis. In: Rothman K, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia: Lippincott Williams and Wilkins. pp. 643-673.
23. Greenland S, O'Rourke K. 2001. On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. Biostatistics 2:463-471.
24. Halbreich U. 2004. Prevalence of mood symptoms and depressions during pregnancy: implications for clinical practice and research. CNS Spectr 9:177-184.
25. Hallberg P, Sjoblom V. 2005. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 25:59-73.
26. Hedges L, Olkin I. 1985. Statistical methods for meta-analysis. Boston: Academic Press.
27. Kallen B, Otterblad OP. 2006. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 21:221-2.
28. Kallen BA, Otterblad OP. 2007. Maternal use of selective serotonin reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79:301-308.
29. Khoury MJ, Moore CA, Levy MJ, Cordero JF. 1992. The interaction between dysmorphology and epidemiology: methodologic issues of lumping and spliting. Teratology 45:135-138.
30. Kulin NA, Pastuszak A, Sage SR, et al. 1998. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 279:609-610.
31. Louik C, Lin A, Werler M, et al. 2006. First trimester exposure to SSRIs and the risk of birth defects. Pharmacoepidemiol Drug Safety 15:S81.
32. Louik C, Lin AE, Werler MM, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675-2683.
33. Malm H, Klaukka T, Neuvonen PJ. 2005. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106:1289-96.
34. Marcus SM, Flynn HA, Blow FC, Barry KL. 2003. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt) 12:373-380.
35. Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. 2008. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG. 115:283-289.
36. Nash CM, O'Connell CM, Howlett AA. 2007. Neonatal outcomes associated with maternal antidepressant use in a population cohort of Nova Scotian pregnancies between 1993 and 2004. Paediatr Child Health 12(SA):42.
37. Oberlander TF, Warburton W, Misri S, et al. 2007. Major congenital anomalies following first trimester serotonin reuptake inhibitor exposure using linked population-based health data. Annual Meeting of the American Pediatric Society. Toronto, Canada. Medical Intelligence Solutions. ID 6280.15.
38. Oberlander TF, Warburton W, Misri S, et al. 2008. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Reprod Toxicol 83:68-76.
39. O'Brien L, Einarson TR, Sarkar M, et al. 2008. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 30:696-701.
40. Schloemp S, Paulus WE, Sterzik K, Stoz F. 2006. Congenital malformations after antidepressant medication associated with paroxetine in early pregnancy? Hum Reprod 21(Sup 1):i12.
41. Simon GE, Cunningham ML, Davis RL. 2002. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159:2055-2061.
42. Sweeting MJ, Sutton AJ, Lambert PC. 2004. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23:1351-1375.
43. Unfred CL, Chambers CD, Felix R, et al. 2001. Birth outcomes among pregnant women taking paroxetine (Paxil): OTIS annual meeting abstract. Teratology 63:321-324.
44. Vial T, Cournot MP, Bernard N, et al. 2006. Paroxetine and congenital malformations: a prospective comparative study. Drug Safety 29:911-1010.
45. Wen SW, Walker M. 2006. The use of selective serotonin reuptake inhibitors in pregnancy. J Obstet Gynaecol Can 26:819-822.